Interestingly, this down-regulation has also been associated with increased sensitivity of RCC tumor cells to mTOR inhibitors, suggesting that lactotransferrin expression may serve as a predictive biomarker for therapeutic efficacy (226). This evidence concerns the gene MTOR and renal cell carcinoma.